Non–Small Cell Lung Cancer Staging: Efficacy Comparison of Integrated PET/CT versus 3.0-T Whole-Body MR Imaging
- 1 August 2008
- journal article
- research article
- Published by Radiological Society of North America (RSNA) in Radiology
- Vol. 248 (2), 632-642
- https://doi.org/10.1148/radiol.2482071822
Abstract
To compare prospectively the diagnostic efficacies of integrated positron emission tomography (PET)/computed tomography (CT) and 3.0-T whole-body magnetic resonance (MR) imaging for determining TNM stages in non-small cell lung cancer (NSCLC). Institutional review board approval and informed consent were obtained. The study included 165 patients (125 men, 40 women; mean age, 61 years) with NSCLC proved at pathologic examination who underwent both unenhanced PET/CT and whole-body MR imaging. Pathologic findings for T (n = 123) and N (n = 150) staging and pathologic or follow-up imaging findings (n = 154) for M staging were reference standards. The efficacies of PET/CT and whole-body MR imaging for lung cancer staging were compared by using the McNemar test. Primary tumors (n = 123 patients) were correctly staged in 101 (82%) patients at PET/CT and in 106 (86%) patients at whole-body MR imaging (P = .263). N stages (n = 150 patients) were correctly determined in 105 (70%) patients at PET/CT and in 102 (68%) patients at whole-body MR imaging (P = .880). Thirty-one (20%) of 154 patients had metastatic lesions. Accuracy for detecting metastases was 86% (133 of 154 patients) at PET/CT, and that at whole-body MR imaging was 86% (132 of 154 patients) (P > .99). Although the differences were not statistically significant, whole-body MR imaging was more useful for detecting brain and hepatic metastases, whereas PET/CT was more useful for detecting lymph node and soft-tissue metastases. Both PET/CT and 3.0-T whole-body MR imaging appear to provide acceptable accuracy and comparable efficacy for NSCLC staging, but for M-stage determination, each modality has its own advantages.Keywords
This publication has 25 references indexed in Scilit:
- Non–Small Cell Lung Cancer: Prospective Comparison of Integrated FDG PET/CT and CT Alone for Preoperative StagingRadiology, 2005
- Detection of Clinically Unexpected Malignant and Premalignant Tumors with Whole-Body FDG PET: Histopathologic ComparisonRadiology, 2004
- Staging of Non–Small-Cell Lung Cancer with Integrated Positron-Emission Tomography and Computed TomographyNew England Journal of Medicine, 2003
- Additional Value of Whole-Body Fluorodeoxyglucose Positron Emission Tomography in the Detection of Distant Metastases of Non–Small-Cell Lung CancerClinical Lung Cancer, 2003
- F-18 fluorodeoxyglucose positron emission tomography staging in radical radiotherapy candidates with nonsmall cell lung carcinomaCancer, 2001
- Whole-Body MR Imaging in 30 Seconds with Real-Time True FISP and a Continuously Rolling Table Platform: Feasibility StudyRadiology, 2001
- Preoperative Staging of Non–Small-Cell Lung Cancer with Positron-Emission TomographyNew England Journal of Medicine, 2000
- Metastases from Non-Small Cell Lung Cancer: Mediastinal Staging in the 1990s—Meta-analytic Comparison Of PET and CTRadiology, 1999
- Staging Non-Small Cell Lung Cancer with Whole-Body PETRadiology, 1999
- Pretreatment Evaluation of Non–Small-cell Lung CancerAmerican Journal of Respiratory and Critical Care Medicine, 1997